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Whether peroxisome proliferator-activated receptor (PPAR) d is a good target for the chemoprevention and/or treatment of
colorectal cancer (CRC) remains controversial. Our goal was to examine PPARd expression in multistage carcinogenesis of the
colorectum and to assess the relevance of PPARd in CRC. Immunohistochemical analysis indicated that PPARd expression increased
from normal mucosa to adenomatous polyps to CRC. In cancer tissues, the PPARd protein was accumulated only in those cancer
cells with highly malignant morphology, as represented by a large-sized nucleus, round-shaped nucleus, and presence of clear nucleoli.
Interestingly, the cancer tissue often contained both PPARd-positive and -negative areas, each retaining their respective specific
morphological features. Moreover, this pattern persisted even when PPARd-positive and -negative cells were aligned next to each
other within a single cancer nest or gland and was present in the majority of CRC cases. Immunohistochemistry for Ki-67 proliferation
marker showed no significant correlation between Ki-67 and PPARd in CRC samples. Based on Western blot analysis and
quantitative RT–PCR, high PPARd protein expression correlated with high PPARd mRNA levels. Peroxisome proliferator-activated
receptor d may have a supporting role in tumorigenesis, and the close association between PPARd expression and malignant
morphology of CRC cells suggests a pivotal role in cancer tissue.
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Peroxisome proliferator-activated receptors (PPARs) are ligand-
activated transcription factors belonging to the nuclear hormone
receptor superfamily. Peroxisome proliferator-activated receptors
play a role in normal physiological processes such as lipid
metabolism and embryo implantation, and they have been
implicated in the disease-related processes of inflammation,
diabetes mellitus, and cancer (Kersten et al, 2000; Willson et al,
2000). To date, three PPAR isoforms, PPARa, PPARd/b, and
PPARg, have been isolated (Willson et al, 2000). Various functions
of the PPARa and g isotypes have been described, such as
involvement in lipid homeostasis, immunity, and cellular differ-
entiation (Tontonoz et al, 1994; Spiegelman 1998; Kliewer et al,
1999). These two isotypes also have clinical significance in the
treatment of dyslipidaemia and type II diabetes mellitus (Rangwala
and Lazar, 2004). In contrast, less is known about the physiological
role of the PPARd isoform, although there is some evidence
supporting its involvement in embryo implantation and develop-
ment (Lim et al, 1999; Barak et al, 2002), epidermal maturation
and wound healing (Di-Poi et al, 2003), and regulation of fatty acid
metabolism (Wang et al, 2003).
Recent studies suggest that PPARd may play a role in colorectal
cancer (CRC). The adenomatous polyposis coli (APC)a n dK-ras
genes are known to play a role in colorectal carcinogenesis
(Vogelstein et al, 1988): PPARd expression and/or activity increase
after loss of the APC gene or activation of K-ras gene expression (He
et al,1 9 9 9 ;S h a oet al, 2002). Cyclooxygenase-2 also modulates
intestinal tumorigenesis (Oshima et al, 1996), and its metabolite,
prostacyclin, increases PPARd activity in CRC cells (Gupta et al,
2000). In addition, PPARd h a sa l s ob e e ns h o w nt ob ead o w n s t r e a m
target of APC/b-catenin/T-cell factor (TCF)-4-mediated transcrip-
tional activation, which is a key mediator in the development of CRC
(He et al, 1999). However, it is currently unclear whether PPARd,
like other downstream targets such as c-myc and cyclin D1 (He et al,
1998; Tetsu and McCormick, 1999), contributes to oncogenesis and
the development of colon tumours. Several studies using Apc
min
mice, designed to evaluate the role of PPARd in colon tumour
development, have produced conflicting findings. Peroxisome
proliferator-activated receptord was found to be unnecessary for
small intestinal polyp formation, but might be required for the
development of large-sized intestinal polyps (Barak et al,2 0 0 2 ) .I n
addition, PPARd attenuates polyp formation in chemical and genetic
models (Harman et al, 2004; Reed et al, 2004). In contrast, activation
of PPARd using a synthetic ligand increases the number and size of
intestinal polyps (Gupta et al, 2004); indeed, PPARd-deficient CRC
cells can establish tumours when grown as xenografts in nude mice
(Park et al, 2001). In this study, we examined expression of PPARd
in multistage carcinogenesis of the colorectum in an effort to
elucidate the role of PPARd in human CRC.
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The IEC18 intestinal cell line was a generous gift from Dr I Bernard
Weinstein (Herbert Irving Comprehensive Cancer Center, College
of Physicians and Surgeons, Columbia University, New York, NY,
USA). They were grown in Dulbecco’s modified Eagle’s medium
plus 10% foetal bovine serum, 100Uml
 1 penicillin, and
100mgml
 1 streptomycin, in 5% CO2 at 371C.
Patients and tissue samples
The expression of PPARd was examined by immunohistochemistry
in the following set of colorectal samples: normal mucosa (n¼32),
adenomatous polyps (n¼23), and various stages of carcinomas
(n¼32). Tissue samples were consecutively collected in the years
2002–2003 during surgery or during endoscopic polypectomy at
the Department of Surgery, Osaka University. None of the patients
had a history of family syndromes for CRC. The samples of normal
mucosa were cut in the longitudinal direction, and the polyps and
carcinomas were cut across the maximum diameter. These samples
were fixed in buffered formalin at 41C overnight, processed
through graded ethanol solutions, and embedded in paraffin. The
resected samples were used with the approval of the ethical
committee of Osaka University. Adenomatous polyps were 16
tubular and seven tubulovillous adenoma.
There were 23 male and nine female CRC patients, with a mean
age of 59.3 years (range, 42–80 years) at surgery. Primary tumours
were distributed in the colon (n¼14) and rectum (n¼18). The
tumours were well-differentiated adenocarcinomas (n¼11), mod-
erately differentiated adenocarcinomas (n¼20), and poorly
differentiated adenocarcinoma (n¼1). Eleven patients had lymph
node metastasis and 21 patients were node-negative. Dukes’
staging classified nine patients as stage A, 10 patients as stage B,
nine patients as stage C, and four patients as stage D.
Antibodies
Rabbit anti-human PPARd polyclonal antibody (sc-7197, H-74)
was obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). This antibody recognises amino acids 2–75 mapping at the
amino-terminus of PPARd of human origin and crossreacts with
mouse and rat PPARd. Mouse anti-human b-catenin monoclonal
antibody was purchased from Transduction Laboratories (Lex-
ington, KY, USA). The rabbit anti-human Ki-67 polyclonal
antibody was purchased from DAKO (Carpinteria, CA, USA).
The rabbit anti-human actin antibody was purchased from Sigma-
Aldrich (St Louis, MO, USA).
Haematoxylin and eosin staining and
immunohistochemistry
Tissue sections (4mm thick) were deparaffinised in xylene,
rehydrated, and stained with haematoxylin and eosin (H&E)
solution. The specimens were histologically diagnosed by two
pathologists from the Department of Pathology, Osaka University.
For immunostaining, sections were mounted on charged glass
slides, boiled for antigen retrieval, and then processed for
immunohistochemistry, as described previously (Takemasa et al,
2000; Yamamoto et al, 2003), using the Vectastain ABC peroxidase
kit (Vector Laboratories, Burlingame, CA, USA). In the primary
antibody reaction, the slides were incubated with appropriate
antibodies for 1h at room temperature. The dilution of each
antibody was 1:40 for PPARd antibody, 1:1000 for b-catenin
antibody, and 1:50 for Ki-67 antibody. For negative control,
nonimmunised rabbit or mouse IgG (Vector Laboratories) or PBS
alone was used as a substitute for the primary antibody to exclude
possible false-positive responses from secondary antibody binding
or from nonspecific binding of IgG. The entire series of samples
was stained twice using separately prepared sections, and no
discrepant staining results were noted.
Immunohistochemical assessment
All immunostained tissue sections were evaluated by two
investigators (TO and HY). Samples were coded without indicating
the clinical and pathological background of the patients. In each
section, 10 high-power fields were selected, and a total of at least
1000 cells were evaluated. The cell populations exhibiting an
association between PPARd expression and malignant morphology
were assessed in the same manner. The results of cytoplasmic
staining were expressed as a percentage of positive cells, and the
intensity of staining was estimated on a scale from 0 to 3 (negative,
weak, moderate, and strong). The total score was determined by
multiplication of the percentage of positive cells and staining
intensity, ranging from 0 to 300, as reported previously (Krajewska
et al, 1996; Shamma et al, 2000). For the assessment of nuclear
expression, the percentage of positive cells was examined because
staining intensity was routine.
Transduction of PPARd complementary DNA (cDNA)
The mammalian expression vector pCMX-mPPARd, encoding
mouse PPARd cDNA (length 1.3kb) was a generous gift from
Professor Ronald M Evans (Salk Institute, San Diego, CA, USA). A
pcDNA3 vector encoding a neomycin-resistant sequence was
purchased from Invitrogen (Carlsbad, CA, USA). Co-transfection
was carried out with pcDNA3 and PPARd plasmid or pCMX vector
at 0.5 and 2mg, respectively, into intestinal IEC18 cells using
Lipofectin Reagent (Life Technologies Inc. Gaithersburg, MD,
USA). Eight hours after transfection, cells were transferred from a
60-mm dish into a 150-mm dish and selected for 10 days in the
presence of 0.9mgml
 1 of G418 (Life Technologies).
Western blot analysis
Western blot analysis was performed as described previously
(Yamamoto et al, 1999). Briefly, the protein samples (50mg) were
separated using 10% polyacrylamide gel electrophoresis, followed
by electroblotting onto a polyvinylidene difluoride membrane. The
membrane was incubated with the primary antibodies at the
appropriate concentrations (1mgml
 1 for PPARd antibody, 1:1000
for actin) for 1h. Protein bands were detected using the Amersham
ECL detection system (Amersham Biosciences Corp., Piscataway,
NJ, USA).
Quantitative real-time PCR for PPARd mRNA
Total cellular RNA was extracted using TRIZOL reagent (Life
Technologies Inc., Gaithersburg, MD, USA). Complementary DNA
was generated from 1mg RNA with avian myeloblastosis virus
reverse transcriptase (Promega, Madison, WI, USA). Quantitative
real-time PCR was performed using LightCyclert (Idaho Technol-
ogy Inc., Salt Lake City, Utah, USA), as described previously
(Yamamoto et al, 2003). Quantification data from each sample
were analysed using LightCyclert analysis software. The tran-
scription value of PPARd was determined by plotting on a
standard curve constructed using HCT116 colon cancer cells. The
amount of each transcript was normalised according to that of
b-actin housekeeping gene quantified with the same sample. The
primer sequences were as follows: b-actin sense, 50-GAAAA
TCTGGCACCACACCTT-30; b-actin antisense, 50-GTTGAAGGTA
GTTTCGTGGAT-30; PPARd sense: 50-GTGGACCTGTCACTGTC
TTGTAC-30; and PPARd antisense: 50-CTTCCTCTTGGAGAAGAT
CAGC-30.
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Statistical analysis was performed using the StatView J-5.0.
program (Abacus Concepts Inc., Berkeley, CA, USA). Associations
between the discrete variables were assessed using Fisher’s exact
tests. Data were reported as mean7s.d., and mean values were
compared using the Mann–Whitney test. P-values o0.05 were
accepted as statistically significant.
RESULTS
Validation of specificity of the anti-PPARd antibody
Immunocytochemistry showed that PPARd-transfected cultures
displayed intense PPARd staining in comparison to the weak
PPARd staining noted in the control cultures (Figure 1A). Western
blotting using anti-PPARd antibody showed that PPARd-intro-
duced cultures displayed prominent bands for the PPARd protein
compared with parental and vector control cells (Figure 1B). These
results indicate that PPARd antibody specifically reacts with the
PPARd protein.
PPARd expression in CRC tissues
In normal colonic mucosa, PPARd protein was detected in the
epithelial cells on the luminal surface of the mucosal glands
(Figure 2A). In adenomatous polyps, PPARd was weakly expressed
in eight of 23 samples (34.8%) in the cytoplasm (Figure 2B). On the
other hand, all the carcinoma tissues expressed the PPARd protein
to various extents, in the cytoplasm and/or nucleus (Figures 2C
and D). More than half of the cancer tissues exhibited nuclear
expression at less than 10%, whereas a considerable number of the
cancer tissues showed cytoplasmic PPARd expression (Table 1).
Peroxisome proliferator-activated receptord expression in adeno-
matous polyps and cancer tissues with regard to their localisation
and expression extent is summarised in Table 1. The differences in
cytoplasmic PPARd expression between adenomatous polyps and
cancers were significant (Po0.0001).
The cancer specimens were divided into two groups (high
expression: n¼15 (46.9%) and low expression: n¼17 (53.1%))
based on the mean value of a cytoplasmic PPARd score of 160 (see
Materials and Methods regarding score determination). Compar-
ison of these two groups showed no differences in the various
clinical and pathological parameters listed in Table 2. In addition,
nuclear expression level (mean value 8.3% at the cutoff point) did
not correlate with clinical and pathological parameters in these two
groups (data not shown).
Western blot analysis
Among the above series, three CRC cases with low cytoplasmic
PPARd and four CRC cases with high cytoplasmic PPARd were
subjected to Western blot analysis to determine PPARd protein
levels (Figure 3A). Colorectal cancer samples expressed various
levels of the PPARd protein that correlated well with those detected
by immunohistochemistry.
Level of PPARd mRNA
The same tissue samples used in Western blot analysis were
subjected to quantitative RT–PCR for PPARd mRNA quantifica-
tion. Samples exhibiting high expression of PPARd protein
generally also exhibited high levels of PPARd mRNA, whereas
those with low PPARd protein levels exhibited low levels of PPARd
mRNA (Figure 3B).
Relationship between PPARd expression and Ki-67
expression
To investigate the possible involvement of PPARd in cell growth,
we compared the expression of PPARd and Ki-67, a cell
Table 1 PPARd expression in colorectal tumour
Nuclear expression
a
% Positive 0–10 10oXo30 30–100
Cancer 20 (62.5%) 10 (31.3%) 2 (6.2%)
Cytoplasmic expression
PPAR score
b 0–50 50oX o150 150–300
Adenoma 18 (78.3%) 5 (21.7%) 0 (0%)













Figure 1 Specificity of anti-PPARd antibody. (A) Immunocytochemistry
with anti-PPARd antibody. After selection with G418 (0.9mgml
 1), pooled
cultures from each dish were stained with anti-PPARd antibody.
Peroxisome proliferator-activated receptor d-transfected cultures of
IEC18 intestinal cells displayed intense PPARd staining in comparison to
the weak PPARd staining noted in the control cultures. (B) Western
blotting using anti-PPARd antibody showed that PPARd-introduced
cultures displayed prominent bands for the PPARd protein compared
with parental and vector control cells.
Figure 2 Immunohistochemistry for PPARd.( A) In normal colonic
mucosa, the PPARd protein was weakly detected in the epithelial cells on
the luminal surface of the mucosal glands. (B) In adenomatous polyps,
PPARd was weakly expressed in the cytoplasm. (C) Cytoplasmic
expression and (D) nuclear expression in carcinoma tissues. Magnifications:
A:  50; B:  20; C:  100; D:  150.
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sproliferation marker, in the serial sections. Nuclear Ki-67-positive
cells were localised at the proliferative zone of the normal
epithelium, but were randomly distributed in cancer tissue
with Ki-67 indices ranging from 22.1 to 80.0% (mean value:
49.6715.1%). Several CRC samples displayed a concordant
distribution of Ki-67-expressing cells and cells with cytoplasmic
accumulation of PPARd (Figure 4), but not nuclear PPARd (data
not shown). Analysis of all the samples, however, found no
significant correlation between the cytoplasmic expression of
PPARd and Ki-67 (data not shown).
PPARd expression and malignant morphology of CRC cells
During the course of this study, we found that the cancer cells with
cytoplasmic accumulation of PPARd often exhibited morphologi-
cal features associated with a highly malignant phenotype. These
features included a large nucleus, globular nuclear shape,
appearance of distinct nucleolus, and loss of cellular polarity
(Figure 5A). In contrast, PPARd-negative cancer cells had
morphological features associated with a low malignant pheno-
type, such as an oval and small nucleus without a distinct
nucleolus, and preserved cellular polarity (Figure 5B). It was of
interest that a cancer tissue often contained both PPARd-positive
and -negative areas, with maintenance of these respective, specific
morphological features (Figure 5C). Moreover, this rule was
maintained even when PPARd-positive and -negative cells were
aligned next to each other within a single cancer nest or gland
(Figure 5D and E). Table 3 summarises the levels of PPARd
expression, nuclear size and shape index, and presence or absence
of a distinct nucleolus in these samples.
Further microscopy analysis, as indicated in the Materials and
Methods, revealed that this association between PPARd expression
and malignant morphological features was a common rule in the
majority of cancer samples tested. Thus, 100% of cancer cells
followed the rule in the 10 CRCs, 50–99% of cancer cells followed
the rule in 18 CRCs, and 1–49% of cells in three CRCs adhered to
the pattern. One CRC sample did not exhibit this association.
DISCUSSION
With regard to human tissue, increased expression of PPARd was
first reported in a small set of CRC tumours (He et al, 1999; Gupta
et al, 2000). To elucidate further the expression and role of PPARd
Table 2 PPARd and clinicopathological characteristics
PPARd
Clinicopathological characteristic n High Low P-value
Age (year)
a 32 60.878.3 58.178.6 0.386
Tumour size (cm)
a 32 4.271.3 4.772.0 0.467
Gender
Male 23 12 11 0.337
Female 9 3 6
Tumour site
Colon 14 7 7 0.755
Rectum 18 8 10
Degree of differentiation
Well 11 6 5 0.519
Mod/por
b 21 9 12
Depth of invasion
Bmp 10 6 4 0.316
ssB 22 9 13
Lymph node metastasis
Absent 21 10 11 0.907
Present 11 5 6
Stage
Dukes A, B 19 10 9 0.430
C, D 13 5 8
Total 32 15 17
Mod¼moderately differentiated adenocarcinoma; mp¼muscularis propria;
PPARd¼peroxisome proliferator-activated receptor d; por¼poorly differentiated
carcinoma; ss¼subserosa; well¼well-differentiated adenocarcinoma.
aData are
mean7s.d.
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Figure 3 (A) Western blot analysis for the PPARd protein. Protein
levels were quantified for three CRC cases with low cytoplasmic PPARd
and four CRC cases with high cytoplasmic PPARd levels. Peroxisome
proliferator-activated receptor d levels in cancer tissues correlated well
with those detected by immunohistochemistry. (B) Quantitative RT–PCR
for PPARd mRNA. The same tissue samples used in Western blot analysis
were subjected to quantitative RT–PCR for PPARd mRNA quantification.
Samples exhibiting high levels of PPARd protein expression generally
exhibited high levels of PPARd mRNA, whereas those with low PPARd
protein levels exhibited low levels of PPARd mRNA.
Figure 4 Comparative immunohistochemistry for PPARd and Ki-67
expression. A concordant distribution of Ki-67-expressing colon cancer
cells and those with cytoplasmic accumulation of PPARd. Magnifications:
 20.
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sin human colorectal tumour, we examined expression of PPARd in
multistage carcinogenesis of the colorectum and found that PPARd
expression increased from normal mucosa to adenomatous polyps
to cancer tissues. Furthermore, we found that PPARd expression
was tightly associated with highly malignant morphology of colon
cancer cells. Thus, the present data suggest a pivotal role of PPARd
in human CRC tissue. These findings are consistent with the recent
reports that PPARd mRNA is overexpressed in more than half of
CRCs (Yang et al, 2006) and that PPARd protein expression is
elevated in adenomas in Apc
min mice and in colon tumours
familial adenomatous polyposis patients (Knutsen et al, 2005).
Although clinicopathological correlations were not obtained with
PPARd expression in CRC, we should emphasise that the relatively
small number of CRC specimens examined may have given a low
statistical power.
In spite of these indications, however, whether PPARd is a good
target for chemoprevention and/or treatment of CRC remains
controversial. It has been reported that a polymorphism in PPARd
modifies the protective effects of nonsteroidal anti-inflammatory
drugs on colorectal adenomas (Siezen et al, 2006), but other
investigators have not reached the same conclusions in the context
of CRC (McGreavey et al, 2005). As mentioned in the Introduction,
PPARd was found to be unnecessary for small intestinal polyp
formation (Barak et al, 2002), but PPARd attenuated polyp
formation in chemical and genetic models (Harman et al, 2004;
Reed et al, 2004). By contrast, it has been reported that inactivation
of the PPARd gene results in reduced tumorigenicity and in vivo
growth of HCT116 colon cancer cells (Park et al, 2001) and that a
specific PPARd agonist enhanced in vivo growth of intestinal
adenoma of Apc
min mice (Gupta et al, 2004). Moreover, a decrease
in PPARd expression by nitric-oxide-donating aspirin isomers was
found to be proportional to their tumour inhibitory effects in
Apc
min mice (Ouyang et al, 2006).
A recent report by Wang et al might be a clue to the puzzle.
They reported that prostaglandin E2-mediated enhancement of
intestinal adenoma of Apc
min mice was negated in Apc
min/
PPARd
 /  mice (Wang et al, 2004a,b). Peroxisome proliferator-
activated receptord may mediate the antiapoptotic effect through
activation by prostacyclin (PGI(2)), a major prostaglandin with
antiapoptotic activity (Gupta et al, 2000; Cutler et al, 2003). There
is also cumulative evidence regarding the antiapoptotic effects of
PPARd in keratinocyte and colon cancer cells (Michalik et al, 2001;
Di-Poi et al, 2002; Shureiqi et al, 2003; Gupta et al, 2004). These
findings suggest that PPARd may play a certain tumour-promoting
role in intestinal tumours or CRC cells by modulating cell survival
and apoptosis, which is in line with our observation that PPARd
was exclusively expressed in those CRC cells that also exhibited
highly malignant morphology.
Cellular atypia is the pathological hallmark for estimating the
malignant potential of lesions. Studies with large numbers of CRC
patients (N¼343, 100, 90, and 64, respectively) (Ambros et al,
1990; Mitmaker et al, 1991; Fernandez-Lopez et al, 1999; Ikeguchi
et al, 1999) have shown that the nuclear area, the large maximum
nucleus diameter, or nuclear shape index, when determined with
the aid of nuclear morphometry, is associated with cancer
metastasis or poor prognosis. During the current study, we found
that PPARd-expressing cancer cells often presented such nuclear
features, whereas PPARd-negative cells did not. Surprisingly, this
association was found in the majority of CRC cases and was
maintained even when PPARd-positive cells and PPARd-negative
cells were positioned next to each other. These findings indicate
that cytoplasmic accumulation of PPARd could be a sensitive
Figure 5 Peroxisome proliferator-activated receptor d expression and
morphology of CRC cells. (A) PPARd-positive cancer cells presented
morphological features associated with high malignant potential including a
large nucleus, globular nuclear shape, appearance of a distinct nucleolus,
and loss of cellular polarity. (B) PPARd-negative cancer cells presented a
morphology (e.g., oval and small nucleus and preserved cellular polarity)
associated with low malignant potential. (C) PPARd-negative and -positive
cancer cells were present within the same CRC tissue, with maintenance of
their respective specific morphological features. This pattern was
maintained even when PPARd-positive and -negative cells were aligned
side by side within a single cancer nest (D) or gland (E). Magnifications:
A–C:  100; D–E: upper panel  20, lower panel  100.
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smarker of CRC cells with the potential for high malignancy.
Recently, Hinoi et al showed that loss of CDX2 was a marker for
large-cell minimally differentiated carcinomas of the colon (Hinoi
et al, 2001), and we are not aware of other molecular markers
tightly associated with CRC cell morphology.
PPARd is known as a nuclear receptor, and we indeed found that
introduction of PPARd cDNA resulted in nuclear expression in
IEC18 cells, whereas immunohistochemistry showed cytoplasmic
accumulation of PPARd in CRC tissues. We believe that the latter
findings do not represent nonspecific binding of the PPARd
antibody in tissue samples; b-catenin staining in the same tumour
series indicated that cytoplasmic PPARd was selectively induced in
CRC cells, possibly as a result of aberrant accumulation of
oncogenic b-catenin (data not shown, our unpublished data).
Therefore, it is postulated that cytoplasmic accumulation of
PPARd may be necessary for the proteins to be available for their
nuclear role whenever required. It is also possible that nuclear
PPARd might be present at a low level but was not detectable
because of the limited sensitivity of the immunohistochemical
analysis.
Our immunohistochemical study of Ki-67 and PPARd did not
identify positive effects of PPARd on in vivo cell growth. We found
by in vitro assay that the growth of intestinal cells was stimulated
by the introduction of PPARd cDNA (data not shown, our
unpublished data), findings that are consistent with other reports
that PPARd enhances the in vitro growth of breast and prostate
cancer cells (Stephen et al, 2004). These results suggest that other
positive and negative regulators could be simultaneously exerting
their effects on cell growth.
In conclusion, the present study using CRC tissue samples
showed that PPARd expression increased during multistage
carcinogenesis. Our data suggest that the association of PPARd
with CRC malignant cellular morphology suggests a pivotal role for
PPARd in these cells.
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A perfect circle was recorded as 1.0.
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